Holen Sie sich die Stockscreener-App
1.71
8.92%
0.14
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by StockNews.com - Defense World
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - ADVFN
AC Immune (ACIU) to Release Earnings on Monday - Defense World
AC Immune’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com to “Hold” - Defense World
Equities Analysts Issue Forecasts for AC Immune Q2 Earnings - Defense World
FY2027 EPS Estimates for AC Immune Cut by HC Wainwright - Defense World
HC Wainwright Lowers AC Immune (NASDAQ:ACIU) Price Target to $12.00 - Defense World
Planning For Perseverance - Life Science Leader
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates - MSN
AC Immune (ACIU) Stock Rating Maintained, Price Target Lowered | - GuruFocus
H.C. Wainwright cuts AC Immune SA target to $12; maintains buy - Investing.com
AC Immune (ACIU) Target Price Reduced by H.C. Wainwright | ACIU Stock News - GuruFocus
AC Immune price target lowered to $12 from $16 at H.C. Wainwright - TipRanks
AC Immune: Q1 Earnings Snapshot - MySA
AC Immune reports Q1 EPS (19c) vs (18c) last year - TipRanks
AC Immune Reports Q1 2025 Financial Results - TipRanks
ACIU Surpasses Revenue Expectations with Strong Phase 2 Data | A - GuruFocus
AC Immune SA Reports Q1 2025 Financial Results and Clinical Advancements in Neurodegenerative Disease Therapies - Nasdaq
AC Immune Q1 Results: Breakthrough in Parkinson's Treatment Shows Promise, Cash Runway Extended to 2027 - Stock Titan
Precision Prevention: The Latest on Alzheimer’s Vaccines - Being Patient
Renaissance Technologies LLC Has $2 Million Stock Position in AC Immune SA (NASDAQ:ACIU) - American Banking and Market News
Individual investors in AC Immune SA (NASDAQ:ACIU) are its biggest bettors, and their bets paid off as stock gained 11% last week - Yahoo Finance
Wells Fargo & Company MN Lowers Stock Holdings in AC Immune SA (NASDAQ:ACIU) - Defense World
Q2 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
Q1 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
AC Immune unveils first-in-class Morphomer targeting pathological α-synuclein - BioWorld MedTech
HC Wainwright Reiterates “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy Rating - TipRanks
AC Immune reports interim outcomes from trial of Parkinson’s therapy - Yahoo Finance
AC Immune (ACIU) Shares Surge on Promising Parkinson's Trial Res - GuruFocus
AC Immune reports Phase II trial of ACI-7104.056 - The Pharma Letter
AC Immune’s Strategic Advances and Financial Highlights - TipRanks
AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study - Nasdaq
AC Immune stock gains on Parkinson’s data (ACIU:NASDAQ) - Seeking Alpha
AC Immune announces additional data from Phase 2 study of VacSYn clinical trial - TipRanks
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune SAACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date - MarketScreener
AC Immune Reports Further Positive Interim Results from - GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - Yahoo
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet - simplywall.st
Short Interest in AC Immune SA (NASDAQ:ACIU) Rises By 23.9% - Defense World
AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewswire
AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):